Market Overview

LifeTech Capital Initiates Marina Biotech at Strong Speculative Buy (MRNA)


LifeTech Capital is out with its report on Marina Biotech (NASDAQ: MRNA), after initiating MRNA at Strong Speculative Buy.

In a note to clients, LifeTech Capital writes, "We believe that Marina Biotech represents one of the potential winners in the relatively new and fragmented RNAi space. In our opinion, success in the space will require advanced technology platforms, an experienced management team and access to development capital, all of which Marina Biotech possesses. Our 12-18 month Price Target of $2.50 is based on a 35x multiple on projected 2015 earnings and discounted 50% to adjust for risk. We have also included a 25% acquisition premium based on Marina Biotech's multiple technology platforms and IP portfolio."

At the time of posting, shares of MRNA were trading at $1.11, up 0.91% from yesterday's close.


Related Articles (MODERNA)

View Comments and Join the Discussion!

Posted-In: LifeTech Capital Marina BiotechAnalyst Color Price Target Analyst Ratings

Latest Ratings

QEPPiper SandlerDowngrades1.0
CALMStephens & Co.Reiterates55.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at